Article

EpiPen Controversy: Mylan CEO Faces Congressional Committee

September 22, 2016

Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.

In her pre-released testimony, Bresch attempted to clarify exactly how much money Mylan makes off each EpiPen sale.

For the rest of this news release, see Pharmaceutical Technology.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser